er is committing to offer all of their prescription medications to Medicaid and it will be at the most favored nation's prices. It's going to have a huge impact on bringing Medicaid cost down uh like nothing else. That was President Trump at the White House on Tuesday announcing that Fizer has agreed to offer most favored nation pricing to Medicaid matching the lowest price offered in other developed nations.Fizer also announced it will participate in a new website that'll be launched next year by the admin ...

As we announce historic steps to confront the crisis of autism. Horrible, horrible crisis. I want to thank the man who brought this issue to the forefront of American politics along with me.And we actually met in my office. Is it like 20 years ago, Bobby. It's probably 20 years ago in New York.I was a developer, as you probably heard, and I always had very strong feelings about autism and how it happened and where it came from. And he and I, I don't know. The word got out, and I wouldn't say that people wer ...

Welcome back. Mark getting FDA approval for an injectable version of its blockbuster cancer therapy. Kitruda Angelica Peoples here with the story fresh off an interview with the CEO.Angelica. Hey Leslie. Well, MK thinks that this shot will be an attractive option for patients since it could be administered in about a minute in a doctor's office versus 30 minutes at a hospital or an infusion center.And the shot's also a way for Merc to manage the IV form of Kruda going off patent in 2028. And Merc hasn't spe ...

Vaccine Policy & Public Health - A federal panel's new rules for COVID shots could reduce vaccine availability [1] - The Advisory Committee on Immunization Practices (ASIP) recommended that individuals under 65 consult a doctor before receiving the COVID vaccine, differing from previous recommendations for all Americans aged 6 months and older [2] - The panel also voted to restrict the use of the MMRV vaccine, advising against its use for children under four years old [2][3] - Childhood vaccination rates have been declining, leading to nearly 1,500 documented measles cases in the US this year, the highest level in over 25 years [10] Historical Context & Impact of Vaccines - In 1900, the US life expectancy was 473%, significantly lower than today's 784% due to infant and child mortality from preventable diseases [5][6] - Before the introduction of the measles vaccine in the early 1960s, the US saw 3 to 4 million measles cases annually, with 400 to 500 deaths [8] - Measles deaths declined by 90% in the decade after the introduction of measles vaccines, and measles was considered eliminated in the US in 2000 [9] - Vaccines are considered a top innovation for contributing to health, longevity, and overall human well-being [14] Skepticism vs Pseudoscience & Public Trust - The discussion around vaccines is not solely scientific, as panels are now populated with vaccine critics, some of whom have profited from that position [16] - It's important to distinguish legitimate skepticism, which is part of science, from pseudoscience, as public trust and polarization are key issues [17][19] - Herd immunity is crucial, and decreased vaccination rates can affect many people [21][22] - Vaccination is a public health issue and a shared responsibility for the safety and health of the community [22][23]

The last word with Ally Veli starts right now. Hey Ally. >> Great conversation with Ezra.Uh not just about the size of the protest which you know Jen this has worked right. I mean this is happening. The the the army parade happened but that day as you and I remember >> the the counterprotests were much much bigger across the country.But the fascinating part is going after groups that organized peacefully. I mean this is this is something that's this is 2025 in our America. It it is and and their group which ...

I just came out of a meeting of the advisory committee on immunization practices. Previously, the CDC had recommended COVID shots for adults, especially for those high risk or who are older. But now, the CDC's ASIP committee has recommended that everyone talk to their doctor individually decide.I worry going forward that there will be um more restrictions to vaccines in the United States. Over the course of its two-day meeting, the committee took up a combined shot for measles, mumps, reubella, and vericell ...

Core Insights - Pfizer (PFE) and AstraZeneca (AZN) are leading players in the oncology sector, with significant revenue contributions from this area [1][2] - Pfizer's oncology sales account for over 25% of total revenues, growing by 9% in H1 2025, while AstraZeneca's oncology sales represent around 43% of total revenues, increasing by 16% in the same period [1][2][11] - Both companies have robust R&D pipelines that are expected to drive future growth [3] Pfizer Overview - Pfizer's acquisition of Seagen in 2023 has bolstered its oncology position [4] - Non-COVID operational revenues are improving, with key products generating $4.7 billion in H1 2025, a 15% operational increase year-over-year [5] - Pfizer anticipates $7.7 billion in cost savings by the end of 2027 and projects a revenue CAGR of approximately 6% from 2025 to 2030 [6] - Challenges include potential declines in COVID-related sales and significant patent expirations expected between 2026 and 2030, impacting key products [7][8] AstraZeneca Overview - AstraZeneca's portfolio includes several blockbuster drugs, with sales exceeding $1 billion, contributing to strong revenue growth [9] - The company plans to launch 20 new medicines by 2030, targeting $80 billion in total revenues [12] - AstraZeneca's newer drugs are contributing positively to top-line growth in 2025 [10] - Challenges include the impact of Medicare Part D redesign on key drug sales and competition from generics and biosimilars [13][14] Financial Estimates and Performance - Pfizer's 2025 sales and EPS estimates indicate modest growth of 0.3% and 1.0%, respectively, with EPS estimates rising from $3.05 to $3.14 [15] - AstraZeneca's 2025 sales and EPS estimates suggest stronger growth of 8.4% and 11.4%, with EPS estimates increasing from $4.50 to $4.58 [16] - Year-to-date stock performance shows Pfizer declining by 9.0%, while AstraZeneca has increased by 17.6% [18] Valuation and Dividend Yield - AstraZeneca's shares trade at a forward P/E ratio of 15.44, while Pfizer's are at 7.79, indicating a more attractive valuation for Pfizer [19] - Pfizer offers a higher dividend yield of 7.1% compared to AstraZeneca's 2.4% [22] - AstraZeneca has a higher return on equity at 32.8% versus Pfizer's 21.4% [22] Investment Outlook - Both companies are rated with a Zacks Rank 3 (Hold), making it challenging to determine a clear investment preference [23] - AstraZeneca is viewed as a safer investment due to its efficient profitability and clearer growth targets, despite Pfizer's attractive valuation and dividend yield [25]

Vaccines Are A Hard Business. RFK Jr.’s CDC Is Making It Even Harder https://t.co/79yKBSH5HY ...

Vaccines Are A Hard Business. RFK Jr.’s CDC Is Making It Even Harder https://t.co/XeQn2ZOcVi ...

Vaccine Hesitancy & Public Health Concerns - Vaccine skepticism stems from confusion and distrust in recommendations, leading to indecision [2][4] - Misinformation and disinformation are key drivers of vaccine rejection among US parents [5] - One in six (16.67%) US parents are rejecting vaccine recommendations due to concerns about side effects and risks [5] - Last year, 271 children died of influenza, with over 90% of them unvaccinated [3] The Role of Scientists & Public Servants - Scientists and public servants have a responsibility to speak out when actions are not in the public's best interest [7][9] - The willingness of scientists to speak out, even leaving the CDC and facing criticism, is crucial for public health [8][9] Impact of Distrust - Efforts to destabilize trust in vaccines and experts, including pediatricians, contribute to indecision and inaction [4]